Zacks Research Issues Pessimistic Estimate for BIO Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Zacks Research reduced their Q2 2025 earnings per share estimates for Bio-Rad Laboratories in a note issued to investors on Thursday, May 22nd. Zacks Research analyst R. Department now expects that the medical research company will earn $2.14 per share for the quarter, down from their previous estimate of $2.91. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.81 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q3 2025 earnings at $2.21 EPS, Q4 2025 earnings at $2.63 EPS, FY2025 earnings at $9.51 EPS, Q1 2026 earnings at $2.82 EPS, Q2 2026 earnings at $2.53 EPS, Q3 2026 earnings at $2.96 EPS, Q4 2026 earnings at $3.03 EPS, FY2026 earnings at $11.35 EPS and Q1 2027 earnings at $2.25 EPS.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, beating the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. The company had revenue of $585.40 million for the quarter, compared to the consensus estimate of $573.01 million. During the same quarter in the prior year, the business earned $2.30 earnings per share. The firm's revenue for the quarter was down 4.2% on a year-over-year basis.

A number of other equities research analysts also recently issued reports on the company. Wells Fargo & Company reduced their price target on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Wall Street Zen downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. UBS Group reduced their price target on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Citigroup reduced their price target on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Finally, Royal Bank of Canada cut their target price on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $327.40.

Bio-Rad Laboratories Price Performance

NYSE:BIO traded down $1.52 during trading hours on Monday, reaching $228.84. 271,857 shares of the company were exchanged, compared to its average volume of 317,495. The company has a market capitalization of $6.23 billion, a P/E ratio of -3.52 and a beta of 1.00. Bio-Rad Laboratories has a 1-year low of $215.38 and a 1-year high of $387.99. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85. The business has a 50 day moving average of $240.51 and a 200 day moving average of $291.87.

Institutional Investors Weigh In On Bio-Rad Laboratories

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC boosted its holdings in shares of Bio-Rad Laboratories by 79.6% during the 1st quarter. Acadian Asset Management LLC now owns 73,431 shares of the medical research company's stock valued at $17,878,000 after acquiring an additional 32,534 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Bio-Rad Laboratories by 95.3% during the 1st quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company's stock valued at $9,105,000 after acquiring an additional 18,239 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of Bio-Rad Laboratories by 14.8% during the 1st quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company's stock valued at $377,000 after acquiring an additional 199 shares in the last quarter. United Services Automobile Association acquired a new stake in shares of Bio-Rad Laboratories during the 1st quarter valued at $292,000. Finally, Caxton Associates LLP acquired a new stake in shares of Bio-Rad Laboratories during the 1st quarter valued at $730,000. 65.24% of the stock is currently owned by institutional investors.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.